Why the study?
Do new oral anticoagulants provide non-inferior or superior efficacy and comparable safety compared to VKA and heparins in patients requiring anticoagulation?
Population
Patients requiring anticoagulation for thromboprophylaxis, thromboembolism, and atrial fibrillation
Comparison
New oral anticoagulants vs Vitamin-K-antagonists and heparins
Design
Review
Authors
Loading...
May support NOAC selection over VKA/enoxaparin; leaves open adherence, high-risk outcomes, and antidote questions.
Do new oral anticoagulants provide non-inferior or superior efficacy and comparable safety compared to VKA and heparins in patients requiring anticoagulation?
New oral anticoagulants show promising efficacy and safety compared to traditional VKAs and heparins, though questions remain regarding adherence, high-risk patients, and the lack of specific antidotes.
Ursula Harbrecht (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: